Today's episode is an interview with Tim Cash, Chief Science Officer of Senolytx Therapeutics, one of the six daughter companies of David Sinclair's Life BioSciences.

In this episode Tim helps me to understand exactly why senescent cells, and the damage they cause to the human body is such an important issue we, as humans, need to fix. If you're interested in learning why and how the human body ages, you're going to love this episode.

We go over the different methods and theories behind fixing senescent cells:
senolytics, senomorphics, and utilizing the immune system to get rid of them naturally, as well as touch on how Senolytx is navigating the regulatory hurdles by focusing on Fibrosis initially, as their main target, with the broader goal of targeting aging as a whole as they progress through clinical trials.

We also go into some of the promising results Senolytx is seeing with their therapies, and Tim enlightens me on some of the most exciting things happening in BioTech right now, and where he see's things in the next 5, 10, and 15 years.

-James Ruhle, SimpleBioTechPodcast.com

Stay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTech

If you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle